伊犁川宁生物技术股份有限公司2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人： 邓旭衡 主管会计工作的负责人：李懿行 会计机构负责人：牛砚 第 3 页 共 3 页 编制单位：伊犁川宁生物技术股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2023年期初 | 2023年1-6月占用 累计发生金额 | 2023年1-6 月占用资金 | 2023年1-6月偿还 | 2023年6月30日 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 会计科目 | 占用资金余额 | （不含利息） | 的利息 （如有） | 累计发生金额 | 占用资金余额 | 因 | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控 ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-048 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》、深圳证券交易所《上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等监管要求及伊犁川宁生物技术股份有限公司（以下简称 "公司"或"本公司"）《募集资金管理制度》的规定，公司编制了 2023 年半年度 募集资金存放与实际使用情况的专项报告，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和到账情况 经中国证券监督管理委员会"证监许可〔2022〕2574 号"文《关于同意伊犁川 宁生物技术股份有限公司首次公开发行股票注册的批复》的批准，公司获准向社会公 众公开发行人民币普通股（A 股）股票 222,800,000 股，每股面值 1.00 元，每股发行 价格为人民币 5.00 元，募集资金总额为 1,114,000,000.00 元。扣除承销保荐费、律师 费用、审计费用、信息披露费用、发行手续费用及其他费用共计 92,316,909.17 元后， 公司本次募集资金净额1,021,683,090.83元，其中超募资金总额为42 ...

证券代码：301301 证券简称：川宁生物 | --- | --- | --- | |--------------|-----------------|-------------| | | 特定对象调研 | □分析师会议 | | | □媒体采访 | ☐业绩说明会 | | 投资者关系 | | | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | 现场参观 | | | | □其他：电话调研 | | | | | | | 参与单位名称 | | | | 及人员姓名 | | | 计 25 人次。 时间 2023 年 7 月 13 日（周四）上午 10:00~13:00 地点 公司四楼会议室 上市公司接待 1、董事会秘书顾祥 人员姓名 2、证券事务专员王乐 1、公司为什么会选址在伊犁地区？ 新疆伊犁地区拥有地理、资源、气候、区位等优势，公 司可以从多维度降低生产成本，使公司产品在激烈的市场竞 争中更具成本优势。 气候方面：公司地处伊犁河谷，当地具有适合生物发酵 的温度、湿度等气候条件，适宜的气候条件能够提高发酵水 平，进而降低公司的生产成本。 原料方面：公司所在地拥有丰富的水资源和煤炭资源、 投资 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-----------------|-------------|------------| | | | | 编号：0004 | | | ☐特定对象调研 | □分析师会议 | | | | □媒体采访 | 业绩说明会 | | | 投资者关系 | | | | | | □新闻发布会 | □路演活动 | | | 活动类别 | | | | | | ☐现场参观 | | | | | □其他：电话调研 | | | | 参与单位名称 | 投资者网上提问 | | | 及人员姓名 时间 2023 年 6 月 16 日（周五）下午 15:00~18:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待 1、董事会秘书顾祥 2、证券事务专员王乐 人员姓名 1、2023 年二季度业绩预计怎么样？ 尊敬的投资者，您好！公司目前经营情况良好。第二季 度具体经营情况将在 2023 年半年 ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-043 伊犁川宁生物技术股份有限公司 关于参加新疆辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，伊犁川宁生物技术股份有限公司（以下 简称"公司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有限 公司联合举办的"2023 年新疆辖区上市公司投资者集体接待日活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）15:30-18:00。届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 伊犁川宁生物技术股份有限公司董事会 2023 年 6 月 6 日 ...

证券代码：301301 证券简称：川宁生物 | --- | --- | --- | |--------------|-----------------------|-------------| | | 特定对象调研 | □分析师会议 | | | □媒体采访 ☐ | 业绩说明会 | | 投资者关系 | | | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | 现场参观 | | | | □其他：电话调研 | | | | | | | | | | | | | | | | | | | | | | | | | | | 参与单位名称 | | | | | | | | 及人员姓名 | | | | | | | | | | | | | | | | | | | | | 券报、21 世纪经济报、 | E | | | 投资者、媒体共计 | 75 人次。 | 时间 2023 年 5 月 25 日 10:00-12:30 地点 公司 5 楼会议室 董事、总经理邓旭衡先生；董事、副总经理、财务总监李懿 上市公司接待 行先生；副总经理、首席科学家赵华先生、副总经理、董事 人员姓名 会秘书顾祥先生。 伊犁川宁生物技术股份 ...

证券代码：301301 证券简称：川宁生物 伊犁川宁生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|-----------------|-----------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | 活动类别 | | | | | □现场参观 | | | | □其他：电话调研 | | | 参与单位名称 | | | | 及人员姓名 | （网址： | https://eseb.cn/14yPfeAv1hm | 时间 2023 年 5 月 15 日 16:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事、总经理邓旭衡先生；董事、副总经理、财务总监李懿 上市公司接待 行先生；副总经理、董事会秘书顾祥先生；副总经理、销售 总监姜海先生；副总经理、首席科学家赵华先生；独立董事 人员姓名 段宏女士；长江证券保荐代表人李忠先生。 1.恭喜公司 22 年营收、净利润双增长， ...

证券代码：301301 证券简称：川宁生物 公告编号：2023-041 伊犁川宁生物技术股份有限公司 关于举办2022年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 05 月 15 日（星期一）16:00-17:00 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 会议问题征集： 投 资 者 可 于 2023 年 05 月 15 日 前 访问网址 https://eseb.cn/14yPfeAv1hm或使用微信扫描下方小程序码进行会前提问，公 司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题 进行回答。 会议召开方式：网络互动方式 二、出席嘉宾 伊犁川宁生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 4 日在巨潮资讯网上披露了《伊犁川宁生物技术股份有限公司 2022 年年度报告》 及《伊犁川宁生物技术股份有限公司 2022 年年度报告摘要》。为便于广大投资 者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 15 日（星期一）16:00-17:00 在"价值在线"（www. ...

Group 1: Company Overview and Performance - The management provided a brief introduction to the company's operations and Q1 performance [3] - The company has developed two agents for its first synthetic biology product, with a sales expectation of 10 tons [3] - The company anticipates a stable increase in the price trend of antibiotic products in 2023 [4] Group 2: Product Development and Market Strategy - The market demand for the product "Red Yeast" is estimated between 500-800 tons, with the main competitor being BASF [4] - The company plans to produce 300 tons of "Red Yeast" annually, with no immediate expansion plans due to current global market demand [5] - The company aims for over 30% gross margin on mature products and over 50% on high-value products [7] Group 3: Financial Management and Cost Control - The company has invested over 2 billion in environmental protection, with limited room for cost reduction in operational expenses [5] - Management expenses have decreased year-on-year due to accounting adjustments [5] - The company has a credit policy for customer payments set at 2-3 months [7] Group 4: Future Outlook and Market Trends - The company expects stable demand for its main products throughout the year, with confidence in achieving profit targets set in the equity incentive plan [5] - The current market price for "Red Yeast" is between 800-1200 RMB/kg, and for 5-Hydroxytryptophan, it is between 800-1000 RMB/kg [7]

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,269,733,317.68, representing a 27.34% increase compared to ¥997,089,543.13 in the same period last year[5] - Net profit attributable to shareholders was ¥174,273,801.35, marking a 74.56% increase from ¥99,834,595.77 year-on-year[5] - Basic and diluted earnings per share increased by 60.00%, from ¥0.05 to ¥0.08[5] - The total operating revenue for Q1 2023 was CNY 1,269,733,317.68, representing an increase of 27.3% compared to CNY 997,089,543.13 in the same period last year[17] - The net profit attributable to the parent company was CNY 175,446,682.72, up 74.4% from CNY 100,595,613.95 in Q1 2022[19] - The total operating costs for Q1 2023 were CNY 1,040,861,350.07, an increase of 18.6% from CNY 876,873,257.88 in the previous year[18] - Research and development expenses amounted to CNY 13,774,801.25, which is a 29.8% increase compared to CNY 10,648,788.15 in Q1 2022[18] - The earnings per share (EPS) for Q1 2023 was CNY 0.08, compared to CNY 0.05 in the same period last year, marking a 60% increase[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥45,161,408.27, a significant decline of 1,587.75% compared to ¥3,035,553.68 in the previous year[11] - The cash flow from operating activities was CNY 497,255,911.49, a decrease from CNY 552,370,253.53 in the same quarter last year[19] - The total cash outflow from operating activities was CNY 569,522,656.06, an increase of 3.6% from CNY 550,549,856.01 in the previous period[21] - The net cash flow from investing activities was -CNY 4,830,726.92, an improvement from -CNY 10,104,116.74 in the previous period[21] - Cash inflow from financing activities was CNY 1,800,000.00, significantly lower than CNY 286,375,700.00 in the previous period[21] - The total cash outflow from financing activities was CNY 552,167,881.27, an increase from CNY 296,878,751.26 in the previous period[21] - The net cash flow from financing activities was -CNY 550,367,881.27, worsening from -CNY 10,503,051.26 in the previous period[21] - The cash and cash equivalents at the end of the period were CNY 1,023,534,016.97, compared to CNY 489,738,911.25 at the end of the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,114,160,972.62, a decrease of 2.66% from ¥10,390,399,359.24 at the end of the previous year[5] - Accounts receivable increased to ¥1,021,309,437.18 from ¥877,597,384.20, reflecting a growth of about 16.3%[15] - Inventory decreased to ¥1,066,692,446.32 from ¥1,383,634,677.19, indicating a reduction of approximately 23.0%[15] - Current liabilities total ¥2,451,994,634.16, down from ¥2,707,385,477.45, a decrease of approximately 9.4%[16] - Long-term borrowings decreased to ¥1,022,999,996.00 from ¥1,428,000,000.00, a reduction of about 28.4%[16] - The total liabilities decreased to CNY 3,728,227,308.83 from CNY 4,179,912,376.97 at the beginning of the year, reflecting a reduction of 10.7%[17] - The deferred income decreased slightly to CNY 33,177,830.24 from CNY 34,240,935.05 at the beginning of the year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,854[12] - Sichuan Kelun Pharmaceutical holds 70.63% of shares, totaling 1,569,887,643 shares[12] - The total equity attributable to shareholders of the parent company increased to CNY 6,379,931,942.92 from CNY 6,204,485,260.20 at the beginning of the year, reflecting a growth of 2.8%[17] Expenses and Taxation - Management expenses decreased by 47.51% to ¥41,062,024.57 from ¥78,226,671.83 in the same period last year[10] - The company experienced a 90.66% increase in income tax expenses, rising to ¥34,938,429.41 from ¥18,324,953.79[10] - The financial expenses for the quarter were CNY 23,979,158.76, down from CNY 37,145,447.06 in the previous year, indicating a reduction of 35.5%[18] - Tax payments increased to CNY 127,956,669.11 from CNY 35,835,646.80 in the previous period, indicating a substantial rise in tax obligations[20] Other Information - The company plans to expand its agricultural land leasing business, which contributed to the increase in right-of-use assets[9] - The company received government subsidies amounting to ¥2,235,251.24, an increase of 74.45% compared to ¥1,281,281.80 in the previous year[10] - The company reported a significant increase in employee compensation payments, totaling CNY 119,280,108.62, up from CNY 98,469,929.66 in the previous period[20] - The company did not conduct an audit for the first quarter report[21] - The company has a goodwill value of ¥1,365,974.00, unchanged from the previous period[16]